MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Open Access Journal of Urology & Nephrology
ISSN: 2578-4676

Dual Cardiorenal Protection in Chronic Kidney Disease: Synergistic Mechanisms of SGLT2 Inhibitors and Non-Steroidal Mineralocorticoid Receptor Antagonists

Matthias Becker* and Anja Richter

Department of Nephrology and Medical Intensive Care, Charité – Universitätsmedizin Berlin, Berlin, Germany

***Corresponding author:** Matthias Becker, Department of Nephrology and Medical Intensive Care, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

Mini Review

Volume 11 Issue 2

Received Date: March 18, 2026

Published Date: April 02, 2026

Abstract

Chronic kidney disease (CKD), whether secondary to diabetes mellitus, hypertension, or glomerulonephritis, has historically been treated with renin-angiotensin system (RAS) inhibitors as the sole pharmacological standard. However, substantial residual risk for end-stage kidney disease (ESKD) and cardiovascular death persists. Over the past five years, the therapeutic paradigm has fundamentally shifted with the clinical validation of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors (dapagliflozin, empagliflozin) and the novel non-steroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone. SGLT2 inhibitors restore tubuloglomerular feedback, reduce intraglomerular pressure, and alleviate renal cortical hypoxia. In parallel, finerenone selectively targets overactivated mineralocorticoid receptors, potent downregulating proinflammatory cytokines, macrophage infiltration, and progressive tubulointerstitial fibrosis. Large landmark clinical trials (DAPA-CKD, EMPA-KIDNEY, FIDELIO-DKD, and FIGARO-DKD) demonstrate profound reductions in CKD progression and heart failure hospitalizations. Moreover, emerging clinical trial evidence (e.g., the CONFIDENCE study) confirms that dual SGLT2i and ns-MRA combination therapy exerts additive cardiorenal benefits while significantly mitigating the incidence of hyperkalemia. This mini-review synthesizes the complementary pathophysiology, landmark trial data, safety parameters, and practical clinical guidelines for implementing dual-pillar therapy in modern nephrology.

Keywords: Chronic Kidney Disease; Sglt2 Inhibitors; Finerenone; Mineralocorticoid Receptor Antagonists; Tubuloglomerular Feedback; Cardiorenal Protection; Albuminuria

Abbreviations

CKD: Chronic Kidney Disease; SGLT2i: Sodium-Glucose Cotransporter-2 Inhibitor; ns-MRA: Non-Steroidal Mineralocorticoid Receptor Antagonist; eGFR: Estimated Glomerular Filtration Rate; UACR: Urinary Albumin-to-Creatinine Ratio; RASi: Renin-Angiotensin System Inhibitor; ESKD: End-Stage Kidney Disease.

Introduction

For over two decades, pharmacological management of chronic kidney disease (CKD) was confined to maximum tolerated renin-angiotensin system (RAS) blockade using

ACE inhibitors or ARBs [1,2]. Despite effective blood pressure reduction, residual albuminuria and inexorable loss of nephron mass remained widespread.

Recent pivotal cardiovascular and renal outcome trials have ushered in a new era of multi-target disease-modifying pharmacotherapy: Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors and non-steroidal mineralocorticoid receptor antagonists (ns-MRAs) [3,4]. These agents provide complementary, non-overlapping hemodynamics and anti-inflammatory mechanisms that fundamentally alter the trajectory of CKD progression.

Complementary Hemodynamic and Cellular Mechanisms

SGLT2 inhibitors act primarily through hemodynamic and metabolic restoration. By inhibiting glucose and sodium reabsorption in the early proximal tubule, they increase distal sodium delivery to the macula densa, restoring tubuloglomerular feedback (TGF) and inducing afferent arteriolar vasoconstriction [5,6]. This alleviates pathological intraglomerular hyperfiltration, normalizes glomerular wall tension, and improves renal cortical oxygenation.

Concurrently, finerenone operates through cellular and structural anti-inflammatory pathways. Unlike steroidal MRAs (spironolactone, eplerenone), finerenone binds with high selectivity and non-steroidal affinity to the mineralocorticoid receptor, blocking ligand-induced nuclear translocation and inhibiting downstream profibrotic mediators such as TGF-β, CTGF, and PAI-1 [7,8]. This prevents extracellular matrix deposition and progressive interstitial glomerulosclerosis (Table 1).

Therapeutic Pillar	Primary Physiological Mechanism	Key Biomarker Impact	Cardiovascular / Renal Benefit	Key Safety & Monitoring Considerations
SGLT2 Inhibitor (Dapagliflozin / Empagliflozin)	Restores tubuloglomerular feedback; afferent arteriolar constriction	Initial eGFR dip (reversible); UACR reduction (30-40%)	37% reduction in CKD progression; 32% reduction in HF hospitalization	Mycotic genital infections; temporary eGFR dip; euglycemic DKA risk
ns-MRA (Finerenone)	Selective non-steroidal MR blockade; anti-fibrotic & anti-inflammatory	UACR reduction (30-35%); suppression of inflammatory cytokines	18% reduction in composite renal endpoints; 14% reduction in MACE	Serum potassium monitoring (baseline, 4 wks); avoid if K+ > 5.0 mmol/L
Dual Combination (SGLT2i + Finerenone)	Simultaneous intraglomerular pressure normalization + anti-fibrotic synergy	Additive UACR reduction (>50%); preserved long-term eGFR slope	Maximal preservation of functional nephrons; reduced HF risk	SGLT2i kaliuresis mitigates finerenone-induced hyperkalemia risk

Table 1: Complementary Cardiorenal Mechanisms, Clinical Efficacy, and Safety of SGLT2i and ns-MRA Therapy.

Clinical Trial Evidence and Hyperkalemia Mitigation

In the FIDELIO-DKD (N = 5,734) and FIGARO-DKD (N = 7,437) trials, finerenone reduced the primary composite renal outcome by 18% and cardiovascular events by 14% in patients with diabetic kidney disease [7,9]. Simultaneously, the DAPA-CKD and EMPA-KIDNEY trials demonstrated 30% to 40% reductions in renal disease progression across both diabetic and non-diabetic CKD etiologies [3,10].

Crucially, combining an SGLT2 inhibitor with finerenone creates a synergistic safety profile: the mild kaliuretic effect of SGLT2 inhibition offsets the potential risk of MRA-induced hyperkalemia, reducing hyperkalemic discontinuations by nearly 50% in pooled analyses [8,9].

Conclusion

The combination of SGLT2 inhibitors and non-steroidal MRAs represents the definitive modern standard of care for progressive chronic kidney disease. Future clinical research must focus on optimizing early initiation in non-diabetic glomerulonephritis and expanding global healthcare access.

References

1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12): 861-869.

2. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, et al. (2001) Renoprotective effect of the angiotensin-receptor

Copyright© Matthias Becker and Anja Richter.

antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12): 851-860.

3. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, et al. (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15): 1436-1446.

4. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23): 2219-2229.

5. Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, et al. (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5): 587-597.

6. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, et al. (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24): 2295-2306.

7. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, et al. (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24): 2252-2263.

8. Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, et al. (2022) Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. Eur Heart J 43(6): 474-484.

9. Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, et al. (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes with and without sodium-glucose cotransporter 2 inhibitor therapy. Circulation 145(13): 996-1005.

10. The EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2): 117-127.

Copyright© Matthias Becker and Anja Richter.